Skip to content

DR40 DataRelease

Release Date: 06/14/2021

SDY1708: Broad dysregulation of innate immunity and hematopoiesis distinguishes mild from severe COVID-19
Status: New
Description: Our understanding of protective vs. pathologic immune responses to Coronavirus disease 2019 (COVID-19) is limited by inadequate profiling of patients at the extremes of the disease severity spectrum. Here, we performed multi-omic single-cell immune profiling of 64 COVID-19 patients across the full range of disease severity, from outpatients with mild disease to fatal cases. Our transcriptomic, epigenomic, and proteomic analyses reveal widespread dysfunction of peripheral innate immunity in severe and fatal COVID-19, with the most profound disturbances including a prominent neutrophil hyperactivation signature and monocytes with anti-inflammatory features. We further demonstrate that emergency granulopoiesis is a prominent feature of fatal COVID-19. Notably, we do not identify substantial immune perturbations in mild COVID-19 in either protein expression, RNA expression, or chromatin regulation, implying that mild disease is characterized by absent or rapidly resolved systemic immune responses. Collectively, our results reveal disease severity-associated immune phenotypes in COVID-19 such as neutrophil hyperactivation that may provide targets for therapeutic intervention such as inhibiting neutrophil function through ligation of neutrophil inhibitory receptors.
NIH Program Metabolic derangements in ARDS
DOI: 10.21430/M3MMUWIVMU
Subjects: 78
Study PI, contact:
Catherine Blish Stanford University School of Medicine Stanford University School of Medicine
William Greenleaf Stanford University School of Medicine Stanford University School of Medicine
Department of Medicine, Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine]
Department of Genetics Stanford University School of Medicine]
Assay TypeNumber of Exp. Samples
CyTOF 146
Clinical Assessments:None